Printer Friendly

ERICKSON NAMED CEO OF TELIOS PHARMACEUTICALS

 ERICKSON NAMED CEO OF TELIOS PHARMACEUTICALS
 SAN DIEGO, Calif., Dec. 20 /PRNewswire/ -- Telios Pharmaceuticals


Inc. today announced the promotion of Robert J. Erickson, Ph.D. to president and chief executive officer from president and chief operating officer.
 Theodor H. Heinrichs will continue as chairman of the board of the San Diego-based company.
 "Dr. Erickson's promotion reflects the board's vote of confidence in his business leadership and scientific judgment toward guiding Telios Pharmaceuticals through our next period of growth," said Heinrichs.
 Erickson joined Telios Pharmaceuticals in 1987, several months after the company's founding. He has more than 20 years' experience in the pharmaceutical and biotechnology industries. Prior to joining the company, he was senior vice president of research and development at Cooper Laboratories Inc. He also served as vice president and technical director of Integrated Genetics, and vice president of research and development for Miles Laboratories' biotechnology group. Erickson is a director of Canji Inc. and UniSyn Fibertec Corp.
 Founded in 1987, Telios Pharmaceuticals is developing therapeutic products based on the company's matrix-peptide technology. Studies by its scientists have shown that the extracellular matrix -- a network of molecules that surrounds all cells in the body -- is critical to the way the body heals itself and combats disease. The company is developing a broad portfolio of products aimed at selectively modifying cell/matrix interactions for a wide range of clinical needs, including the treatment of critical fibrotic diseases, the control of platelet aggregation, dermal and opthalmic tissue regeneration, and biocompatible coatings of implants.
 -0- 12/20/91
 /CONTACT: Audrey L. Dickason of Telios Pharmaceuticals, 619-597-6109; or Charles Versaggi of Versaggi & Associates, 408-358-4162, for Telios Pharmaceuticals/ CO: Telios Pharmaceuticals ST: California IN: MTC SU: PER


RM -- SJ005 -- 4528 12/20/91 16:44 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 20, 1991
Words:291
Previous Article:TWO NEW MEMBERS ELECTED TO BG&E BOARD OF DIRECTORS
Next Article:ART'S-WAY SECOND QUARTER AND 6 MONTH RESULTS
Topics:


Related Articles
DECORIN MAY PREVENT PROGRESSION OF KIDNEY DISEASE UTAH AND CALIFORNIA SCIENTISTS REPORT
TELIOS ANNOUNCES NORSK HYDRO DECISION
TELIOS APPOINTS FORMER ELI LILLY & COMPANY EXECUTIVE DONALD W. GRIMM AS CHIEF EXECUTIVE OFFICER
Telios Pharmaceuticals Names Dr. Juerg Tschopp Senior Director of Research and Development

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters